Combination of two study drugs for advanced pancreatic and other solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Skin clinical trials.
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must have advanced or spread, and standard treatments either haven't worked or aren't available.
- You need to be well enough to be up and about for at least half of your waking hours (ECOG 0-2).
- For the melanoma group, your tumor must have specific gene changes (like NRAS, KRAS, or HRAS) and you must have already tried a PD-1/PD-L1 inhibitor (immunotherapy) unless you can't take it.
- You must have adequate organ function (heart, kidney, liver, blood counts) and be willing to have tumor samples taken if in the expansion group.
- You must agree to use effective birth control during the trial and avoid certain foods and medicines that could interact with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (including an investigational immunotherapy and a targeted pill, plus standard chemotherapy) as the first treatment for pancreatic cancer that cannot be removed with surgery. It may help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This trial offers access to ulixertinib, an oral drug that targets specific genetic changes (MAPK pathway) in advanced cancers. It is for people who have run out of standard options and may benefit from this targeted treatment.
This study tests a combination of drugs (an investigational immunotherapy, a targeted therapy, and chemotherapy) as a second-line treatment for people with advanced pancreatic cancer. The goal is to see if this combination can help slow down or stop the cancer when the first treatment no longer works.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.